Octreotide Acetate

CAS 83150-76-9 23 current records 3 historicalPeptide

Who holds supplier records for Octreotide Acetate? 23 organisations hold a current record for Octreotide Acetate: an active US FDA Type II Drug Master File. A further 3 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (6), China (4), United States (2), Italy (2) and 4 other countries (4); not recorded for 5.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Octreotide Acetate: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/octreotide-acetate

Reading the evidence

  • 23 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 9 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (23)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Octreotide Acetate. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Octreotide Acetate sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (3)

Organisations whose Type II DMFs for Octreotide Acetate are no longer active. These show a past filing, not current supply.

Show all 3 historical records
  • HEMMO PHARMACEUTICALS PVT LTD
    Inactive DMF 26330 · filed Jun 2012
  • India · Inactive DMF 22068 · filed Oct 2008
  • BACHEM AMERICAS INC
    Inactive DMF 16760 · filed Aug 2003

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Octreotide Acetate is a synthetic octapeptide that mimics natural somatostatin pharmacologically, inhibiting the secretion of several hormones. It is primarily used in the treatment of acromegaly and severe cases of diarrhea associated with metastatic carcinoid tumors and vasoactive intestinal peptide tumors.

Chemical identity

IUPAC name
acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
Canonical SMILES
C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O.CC(=O)O.CC(=O)O
InChIKey
QWFYIFWTVZFPRY-LODIGNQBSA-N
Synonyms
Sandostatin API, bynfezia, mycapssa, octreolin, octreotide (as acetate), sandostatin, sms 201-995 ac, sms-201-995 ac, sms-201995-ac

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Somatostatin Analog
Mechanism of action
Somatostatin Receptor Agonists

Therapeutic areas

EndocrinologyOncologyGastroenterology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Octreotide Acetate?

23 organisations hold an active US FDA Type II Drug Master File or a CEP for Octreotide Acetate: Sun Pharmaceutical Industries Limited (India), Alembic Pharmaceuticals Limited (India), ALP PHARM BEIJING CO LTD, AMBIO INC (United States), AURO PEPTIDES LTD, BACHEM AG, BCN PEPTIDES SA (Spain) and CHEMI SPA (Italy), and 15 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Octreotide Acetate Drug Master Files are active?

Sun Pharmaceutical Industries Limited (DMF 27990, 17678), Alembic Pharmaceuticals Limited (DMF 37913), ALP PHARM BEIJING CO LTD (DMF 30992), AMBIO INC (DMF 27759), AURO PEPTIDES LTD (DMF 29448), BACHEM AG (DMF 34145), BCN PEPTIDES SA (DMF 18740) and CHEMI SPA (DMF 19567) and 15 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Octreotide Acetate records mean?

3 organisations have only inactive Type II DMFs for Octreotide Acetate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Octreotide Acetate supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Octreotide Acetate?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.